What is Zacks Research’s Estimate for Soligenix Q2 Earnings?

Soligenix Inc. (NASDAQ:SNGX) – Zacks Research raised their Q2 2026 earnings per share estimates for Soligenix in a research note issued on Thursday, May 14th. Zacks Research analyst D. Bautz now expects that the biopharmaceutical company will post earnings per share of ($0.22) for the quarter, up from their prior estimate of ($0.30). The consensus estimate for Soligenix’s current full-year earnings is ($1.14) per share. Zacks Research also issued estimates for Soligenix’s Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.72) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Soligenix presently has an average rating of “Hold” and a consensus target price of $6.00.

Soligenix Trading Up 13.5%

SNGX opened at $0.41 on Tuesday. Soligenix has a twelve month low of $0.28 and a twelve month high of $6.23. The stock has a market cap of $6.06 million, a PE ratio of -0.24 and a beta of 1.31. The business’s 50 day moving average is $0.99 and its 200-day moving average is $1.22.

Soligenix (NASDAQ:SNGX) last issued its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02.

Hedge Funds Weigh In On Soligenix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Soligenix during the 4th quarter worth approximately $37,000. Jane Street Group LLC purchased a new position in shares of Soligenix during the 4th quarter valued at $51,000. StoneX Group Inc. purchased a new position in shares of Soligenix during the 4th quarter valued at $50,000. Geode Capital Management LLC grew its holdings in shares of Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 37,811 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of Soligenix during the 3rd quarter valued at $821,000. 3.60% of the stock is currently owned by hedge funds and other institutional investors.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.